2065-75-0

Basic information

• Product Name: 2-Bromomalonaldehyde
• Synonyms: 2-BroMo-1,3-propanedialdehyde;2-broMo-1,3-propanedial;Propanedial, 2-broMo-;Bromomalonaldehyde 97%;2-Bromomaloldehyde;2-Bromomalondialdehyd for synthesis;BROMOMALONALDEHYDE;2-BROMOMALONALDEHYDE
• CAS NO: 2065-75-0
• Molecular Formula: C₃H₃BrO₂
• Molecular Weight: 150.96
• Product Categories: Aldehydes;blocks;Bromides;Aldehyde Labeling Reagents;C1 to C6;Carbonyl Compounds
• Mol File: 2065-75-0.mol
• Article Data: 10

Chemical Properties

• Melting Point: 132-136 °C(lit.)
• Boiling Point: 134.8 °C at 760 mmHg
• Flash Point: 69.5 °C
• Appearance: Light yellow sSolid
• Density: 1.75 g/cm³
• Vapor Pressure: 7.95mmHg at 25°C
• Refractive Index: 1.468
• Storage Temp.: Keep Cold
• Solubility: Acetonitrile (Slightly), DMSO (Slightly)
• PKA: 1.70±0.10(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 2-Bromomalonaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromomalonaldehyde(2065-75-0)
• EPA Substance Registry System: 2-Bromomalonaldehyde(2065-75-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 2065-75-0(Hazardous Substances Data)

Usage

Description

2-Bromomalonaldehyde is a light yellow solid that is used in the formation of glyoxal-derived adducts from substituted guanines.

Uses

Used in Chemical Research:
2-Bromomalonaldehyde is used as a reagent for the synthesis of glyoxal-derived adducts from substituted guanines, which is important for studying the chemical properties and reactions of these compounds.
Used in Pharmaceutical Industry:
2-Bromomalonaldehyde is used as an intermediate in the synthesis of various pharmaceutical compounds, particularly those targeting guanine residues in DNA or RNA, which can have potential applications in drug discovery and development.
Used in Material Science:
2-Bromomalonaldehyde can be used as a building block in the development of new materials with specific properties, such as those with unique optical, electronic, or mechanical characteristics, by forming adducts with substituted guanines.

InChI:InChI=1/C3H3BrO2/c4-3(1-5)2-6/h1-3H

Upstream product

• 4704-87-4 2-bromo-1,3-propanediol 
• 102-52-3 malonaldehydebis(dimethylacetal) 
• 77809-07-5 2,2-dibromo-3-bromomethyl-oxirane 
• 20760-42-3 3-chloro-1,3-diethoxy-propene 
• 117291-86-8 (E)-2,3-dibromo-propenal 
• 35542-75-7 2-bromo-1,1,3,3-tetraethoxy-propane 

Downstream Products

• 1003-60-7 2-methylthiazole-4-carboxyaldehyde 
• 753027-61-1 N²-carboxymethyl-1,N²-(trans-1,2-dihydroxyethano)-9-ethylguanine 
• 957062-56-5 4-bromo-1-(4-fluorophenyl)-1H-pyrazole 
• 1027511-41-6 ethyl 6-bromopyrazolo[1,5-a]pyrimidine-3-carboxylate 
• 7752-78-5 5-bromo-2-methylpyrimidine 
• 38696-20-7 2-phenyl-5-bromopyrimidine 
• 721920-84-9 2-(4-chloro-phenyl)-thiazole-5-carbaldehyde 
• 705263-10-1 6-bromo-pyrazolo[1,5-α]pyrimidine 
• 1002107-31-4 2-methyl-1-phenyl-1H-imidazole-5-carbaldehyde 
• 1002107-35-8 2-methyl-1-(4-nitrophenyl)-1H-imidazole-5-carbaldehyde 
• 1002107-42-7 2-methyl-1-(3-(trifluoromethyl)phenyl)-1H-imidazole-5-carbaldehyde 
• 1002107-41-6 1-(2-methylphenyl)-2-methyl-1H-imidazole-5-carbaldehyde 
• 1002107-40-5 1-(2,6-difluorophenyl)-2-methyl-1H-imidazole-5-carbaldehyde 
• 1002107-39-2 1-(4-methoxyphenyl)-2-methyl-1H-imidazole-5-carbaldehyde 

Relevant articles and documents

BSA binding and antibacterial studies of newly synthesized 5,6-Dihydroimidazo[2,1-b]thiazole-2-carbaldehyde

A new heterocyclic compound, 5,6-Dihydroimidazo[2,1-b]thiazole-2-carbaldehyde (ITC) was synthesized and its antibacterial activity and also its interaction with bovine serum albumin (BSA) were studied. The structure of the synthesized compound was confirmed by 1H NMR, 13C NMR and IR spectroscopic techniques. The antibacterial activity was carried out by minimum inhibitory concentration (MIC) method. The compound showed a good antibacterial activity. The mechanism of interaction between the BSA and ITC under physiological conditions was investigated by various molecular spectroscopic techniques like, fluorescence, circular dichroism (CD), UV absorption and FT-IR. The interaction between ITC and BSA was followed by studying the quenching of intrinsic fluorescence of BSA upon the addition of ITC at three different temperatures. The binding constant (K), Stern-Volmer quenching constant (Ksv) and number of binding sites were determined. The separation distance between BSA and ITC was evaluated based on the fluorescence resonance energy transfer theory. The conformational changes in BSA upon binding of ITC were also confirmed. The interference of some metal ions on interaction was studies. The displacement studies with site specific markers confirm that the site III was the binding site for ITC on BSA.

Method for synthesizing 5-bromo-7-azaindole

The invention provides a method for synthesizing 5-bromo-7-azaindole, and belongs to the field of medicinal chemical synthesis. The method comprises the following steps: reacting a raw material 1,1,3,3-tetramethoxypropane 2 with bromine to obtain an intermediate 3, preparing an intermediate 4 from an intermediate 3 under the action of an alkali, and reacting the intermediate 4 with 2-aminopyrroleto obtain the 5-bromo-7-azaindole 1. The method has the advantages of few reaction steps, easily available raw materials, high yield, small pollution, and easiness in amplified production.

Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema

Vascular adhesion protein-1 (VAP-1), an amine oxidase that is also known as a semicarbazide-sensitive amine oxidase (SSAO), is present in particularly high levels in human plasma, and is considered a potential therapeutic target for various inflammatory diseases, including diabetes complications such as macular edema. In our VAP-1 inhibitor program, structural modifications following high-throughput screening (HTS) of our compound library resulted in the discovery that thiazole derivative 10, which includes a guanidine group, shows potent human VAP-1 inhibitory activity (IC50 of 230 nM; rat IC 50 of 14 nM). Moreover, compound 10 exhibited significant inhibitory effects on ocular permeability in STZ-induced diabetic rats.